X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Biocon Ltd with Aurobindo Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON vs AUROBINDO PHARMA - Comparison Results

BIOCON      Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

AUROBINDO PHARMA 
   Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON AUROBINDO PHARMA BIOCON /
AUROBINDO PHARMA
 
P/E (TTM) x 19.3 14.2 135.8% View Chart
P/BV x 3.0 2.9 106.0% View Chart
Dividend Yield % 0.4 0.4 87.3%  

Financials

 BIOCON    AUROBINDO PHARMA
EQUITY SHARE DATA
    BIOCON
Mar-18
AUROBINDO PHARMA
Mar-18
BIOCON /
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs1,188809 146.8%   
Low Rs305504 60.5%   
Sales per share (Unadj.) Rs68.7281.1 24.5%  
Earnings per share (Unadj.) Rs7.641.4 18.3%  
Cash flow per share (Unadj.) Rs14.050.9 27.5%  
Dividends per share (Unadj.) Rs1.002.50 40.0%  
Dividend yield (eoy) %0.10.4 35.2%  
Book value per share (Unadj.) Rs86.3199.4 43.3%  
Shares outstanding (eoy) m600.00585.88 102.4%   
Bonus/Rights/Conversions IS--  
Price / Sales ratio x10.92.3 465.0%   
Avg P/E ratio x98.915.9 622.7%  
P/CF ratio (eoy) x53.412.9 414.1%  
Price / Book Value ratio x8.63.3 262.5%  
Dividend payout %13.26.0 219.1%   
Avg Mkt Cap Rs m447,900384,630 116.4%   
No. of employees `0006.117.3 35.5%   
Total wages/salary Rs m9,31121,308 43.7%   
Avg. sales/employee Rs Th6,705.89,500.7 70.6%   
Avg. wages/employee Rs Th1,514.21,229.4 123.2%   
Avg. net profit/employee Rs Th736.91,397.9 52.7%   
INCOME DATA
Net Sales Rs m41,234164,666 25.0%  
Other income Rs m2,0621,020 202.2%   
Total revenues Rs m43,296165,686 26.1%   
Gross profit Rs m8,29137,718 22.0%  
Depreciation Rs m3,8515,580 69.0%   
Interest Rs m615777 79.1%   
Profit before tax Rs m5,88732,380 18.2%   
Minority Interest Rs m21331 678.3%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,5698,183 19.2%   
Profit after tax Rs m4,53124,229 18.7%  
Gross profit margin %20.122.9 87.8%  
Effective tax rate %26.725.3 105.5%   
Net profit margin %11.014.7 74.7%  
BALANCE SHEET DATA
Current assets Rs m41,486121,878 34.0%   
Current liabilities Rs m21,41386,806 24.7%   
Net working cap to sales %48.721.3 228.6%  
Current ratio x1.91.4 138.0%  
Inventory Days Days64130 49.2%  
Debtors Days Days9468 137.7%  
Net fixed assets Rs m50,66181,037 62.5%   
Share capital Rs m3,000586 512.0%   
"Free" reserves Rs m48,808116,218 42.0%   
Net worth Rs m51,808116,804 44.4%   
Long term debt Rs m17,8984,512 396.7%   
Total assets Rs m99,897211,052 47.3%  
Interest coverage x10.642.7 24.8%   
Debt to equity ratio x0.30 894.3%  
Sales to assets ratio x0.40.8 52.9%   
Return on assets %5.211.8 43.5%  
Return on equity %8.720.7 42.2%  
Return on capital %9.627.4 35.2%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m12,05880,727 14.9%   
Fx outflow Rs m7,34834,700 21.2%   
Net fx Rs m4,71046,027 10.2%   
CASH FLOW
From Operations Rs m6,62119,548 33.9%  
From Investments Rs m-6,840-19,570 35.0%  
From Financial Activity Rs m-2,3978,642 -27.7%  
Net Cashflow Rs m-2,6128,922 -29.3%  

Share Holding

Indian Promoters % 40.4 54.1 74.7%  
Foreign collaborators % 20.6 0.0 -  
Indian inst/Mut Fund % 8.4 8.0 105.7%  
FIIs % 10.7 27.7 38.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 19.9 10.2 195.1%  
Shareholders   109,995 69,601 158.0%  
Pledged promoter(s) holding % 0.0 8.6 0.5%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON With:   WYETH LTD  PIRAMAL ENTERPRISES  JUBILANT LIFE SCIENCES  SUN PHARMA  PFIZER  

Compare BIOCON With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices End on a Positive Note for Third Straight Day; Yes Bank Falls 5%(Closing)

Indian share markets traded on a positive note most of the day and ended marginally higher. Sectoral indices ended on a mixed note with stocks in the IT sector.

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 10.9% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 10.9% YoY). Sales on the other hand came in at Rs 53 bn (up 30.7% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

BIOCON Announces Quarterly Results (4QFY19); Net Profit Down 53.8% (Quarterly Result Update)

Apr 26, 2019 | Updated on Apr 26, 2019

For the quarter ended March 2019, BIOCON has posted a net profit of Rs 705 m (down 53.8% YoY). Sales on the other hand came in at Rs 8 bn (down 34.7% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 19.3% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, AUROBINDO PHARMA has posted a net profit of Rs 7 bn (up 19.3% YoY). Sales on the other hand came in at Rs 53 bn (up 21.5% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

BIOCON LTD Announces Quarterly Results (3QFY19); Net Profit Up 169.2% (Quarterly Result Update)

Jan 28, 2019 | Updated on Jan 28, 2019

For the quarter ended December 2018, BIOCON LTD has posted a net profit of Rs 2 bn (up 169.2% YoY). Sales on the other hand came in at Rs 15 bn (up 45.6% YoY). Read on for a complete analysis of BIOCON LTD's quarterly results.

AUROBINDO PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 19, 2018 | Updated on Dec 19, 2018

Here's an analysis of the annual report of AUROBINDO PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of AUROBINDO PHARMA. Also includes updates on the valuation of AUROBINDO PHARMA.

More Views on News

Most Popular

These 3 Smallcap Stocks are Set to Make the Most of Smallcap Rebound(Profit Hunter)

Jul 9, 2019

As the sense of normalcy returns to the markets, the rebound in the quality smallcaps could be huge.

2 Stocks from Super Investor Sanjay Bakshi's Portfolio You Can Bet On...(The 5 Minute Wrapup)

Jul 12, 2019

Despite the current fear prevailing in the markets, both these stocks have the potential to deliver in 4-5 years.

A One Stock Crorepati(Profit Hunter)

Jul 4, 2019

Do you wish you could become a crorepati in the stock market? Read on...

After Disappointing Budget, Here's a Document that Concerns Largecap and Smallcap Investors(The 5 Minute Wrapup)

Jul 8, 2019

A new 'definition' of the stock universe that triggered the smallcap sell-off is back with the latest list...

Union Budget 2019-2020: More Style Over Substance(The 5 Minute Wrapup)

Jul 5, 2019

Did the Union Budget announce measures to stimulate the economy and bolster corporate earnings growth?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON SHARE PRICE


Jul 17, 2019 (Close)

TRACK BIOCON

BIOCON - CADILA HEALTHCARE COMPARISON

COMPARE BIOCON WITH

MARKET STATS